| P50 | author | Jean-Daniel Lalau | Q86205680 |
| | Marc E. De Broe | Q107477289 |
| P2093 | author name string | Farshad Kajbaf | |
| | Paul Arnouts | |
| | Marc de Broe | |
| P2860 | cites work | Use of metformin in the setting of mild-to-moderate renal insufficiency | Q22241290 |
| | Clinical Pharmacokinetics of Metformin | Q22241422 |
| | Contraindications to the use of metformin | Q22242091 |
| | Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q24642503 |
| | The epidemiology and management of diabetes mellitus in Indonesia | Q30939574 |
| | Lactic acidosis induced by metformin: incidence, management and prevention | Q33654578 |
| | Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations | Q33873111 |
| | Metformin's contraindications should be contraindicated. | Q33920606 |
| | Lactic acidosis in metformin therapy: searching for a link with metformin in reports of 'metformin-associated lactic acidosis'. | Q33951985 |
| | Drug Therapy in Patients With Chronic Renal Failure | Q34206012 |
| | Metformin: effective and safe in renal disease? | Q34764759 |
| | Use of Metformin in Patients with Kidney and Cardiovascular Diseases | Q35688570 |
| | Roles of the liver and kidney in acid-base regulation and its disorders | Q37354504 |
| | Treatment of type 2 diabetes in Latin America: a consensus statement by the medical associations of 17 Latin American countries. Latin American Diabetes Association | Q37838739 |
| | Clinical pharmacokinetics of metformin | Q41066472 |
| | Metformin therapy in patients with chronic kidney disease. | Q42647268 |
| | Old Age May Not Be a Contraindication to the Use of Metformin | Q42781618 |
| | Limitations of metformin use in patients with kidney disease: are they warranted? | Q42846858 |
| | Metformin-associated lactic acidosis: a prognostic and therapeutic study. | Q45987007 |
| | Kidney function and age are both predictors of pharmacokinetics of metformin. | Q46035485 |
| | Metformin in renal failure--weigh the evidence. | Q46038686 |
| | Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how? | Q46241434 |
| | Introducing estimated glomerular filtration rate (eGFR) into clinical practice in the UK: implications for the use of metformin | Q51919658 |
| | Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | Q57412648 |
| | Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations | Q77407120 |
| | Establishing pragmatic estimated GFR thresholds to guide metformin prescribing | Q80729420 |
| | Inappropriate metformin prescribing in elderly type 2 diabetes mellitus (T2DM) patients | Q84031646 |
| | About the discrepancies between consensus documents, clinical practice guidelines, and legal regulations in the treatment of type 2 diabetes | Q84582382 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metformin | Q19484 |
| | kidney disease | Q1054718 |
| P304 | page(s) | 1027-1035 | |
| P577 | publication date | 2013-08-19 | |
| P1433 | published in | Pharmacoepidemiology and Drug Safety | Q15759496 |
| P1476 | title | Metformin therapy and kidney disease: a review of guidelines and proposals for metformin withdrawal around the world | |
| P478 | volume | 22 | |